Peking University First Hospital

HONG KONG and SHANGHAI, June 19, 2024 /PRNewswire/ -- The "Ping An Family Doctor Brand Upgrade Conference" was held in Shanghai recently. Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318 / 82318; SSE: 601318) has upgraded its "Ping An Family Doctor" brand with a one-stop, proactive health management services system and a commitment to providing "proactive health management, chronic disease control, and full disease management" to users. Michael Guo, Group Co-CEO, said, "As a world-leading financial brand, Ping An never forgets its original aspiration and vision, remains customer-needs oriented and provides customers worry-free, time-saving, and money-saving healthcare services, to further promote the high quality, systemic and standardized development of 'Internet + Family Doctor', and support the national 'Healthy China' vision." During the conference, Prof. Chi Chunhua, Chairperson-designate, General Practice Branch of Chinese Medical Association said that, as China's population aging trend intensifies, the public's health needs are becoming more diversified and complex. To meet the growing health needs of the public, developing family doctor services and searching for a better service operation model has become an inevitable trend in the new era health system reform. "There is still a long way to go to achieve high-quality development of family doctor contract services. The entire society should work together, to continue explore the family doctor contract service model, and utilize advanced internet technology to optimize and improve service scope and streamline processes," she said. Building a one-stop, proactive health management services system Ping An Health, the flagship of the Ping An Group's healthcare and senior care ecosystem, focuses on delivering "family doctor" and "senior care concierges" services, and has evolved into a one-stop provider of professional, comprehensive, high-quality health and senior care management services. As of 2023, users with family doctor membership were close to 13 million, with more than 98% of users indicating 100% satisfaction with its medical consultation service. Ping An Health's upgraded "Ping An Family Doctor" introduces a comprehensive one-stop proactive health management services system. Customers are offered worry-free, time-saving, and money-saving one-stop family healthcare management services through the support of a dedicated family doctor. The one-stop proactive health management services system includes: 1) a team of professional family doctors holding dual certification from Peking University International Hospital and the World Organization of Family Doctors (WONCA); 2) a 5A standard service process guided by the General Practice Branch of the Chinese Medical Association and certified by the Royal Australian College of General Practitioners (RACGP); 3) proactive health management services tailored to the needs of sub-healthy individuals, patients with chronic diseases, and people with medical conditions; and 4) providing 12 scarce medical resources to those in need. "Ping An Family Doctor" also announced its commitment to providing "proactive health management, chronic disease control, and full disease management". The commitment translates into different actions for different patient groups. For sub-healthy individuals, "Ping An Family Doctor" develops high-quality health management plans through automated health records and instant interpretation of physical examination reports. This enables timely physical examination and early treatment interventions. For chronic disease patients, "Ping An Family Doctor" combines Internet of Things (IoT) real-time monitoring and high-risk warnings with a 21-day lifestyle management program to help relieve chronic disease symptoms. For individuals with medical conditions, "Ping An Family Doctor" offers comprehensive disease management, including: 24/7 immediate pre-hospitalization consultations, precise recommendations for renowned doctors and hospitals and appointment registration assistance, full-time nursing service and care during hospitalization to ensure efficient treatment, and personalized "recovery guides" and follow-up visits after hospitalization for a smooth recovery. Exploring new ways to "synergize healthcare and insurance" for family doctor services The enhancement of "Ping An Family Doctor" is supported by the use of leading medical technology. Ping An Health has developed five significant databases over the years: for diseases, prescriptive medicine, medical products, medical resources and personal healthcare. The company has developed the world's most comprehensive knowledge map in the medical field. It has constructed an innovative multimodal medical large language model (LLM) and 12 artificial intelligence (AI) business models on this foundation. The "Ping An Doctor's Assistant" workbench of Ping An Health is capable of autonomously updating files and matching health plans, thereby simplifying the process of health management process. Additionally, Ping An employs AI for materialize a 100% quality check of all services, such as online consultations, electronic medical records, and prescription quality control, in order to ensure the safety and compliance of "Ping An Family Doctor". Ping An's "insurance + healthcare" business strategy has been particularly successful in recent years. Healthcare and insurance synergy is a novel approach that seamlessly integrates distinct medical and healthcare services with the financial businesses of the payors, such as insurance. For instance, the "Ping An Zhen Xiang RUN 2023 Health Services Plan" of Ping An Life Insurance and Ping An Health, which offers health management services, including health, chronic diseases, and medical care, as well as wealth management and risk protection requirements for customers. The number of Ping An Life insurance customers that also used Ping An's healthcare services surpassed 20 million in 2023, with a service satisfaction rate of 99% and double-digit year-on-year growth. Looking forward, Ping An Health will further consolidate its family doctor service system, which serves as its primary business segment, and will focus on providing exceptional proactive health management solutions that are tailored to the growing medical and health needs of the general public. Meanwhile, Ping An Health will make substantial investments in the health and senior care ecosystem and continue to develop a distinctive development trajectory of the Chinese "managed care model." Additionally, the Company will strengthen its partnerships with financial and corporate clients for ensure the enterprise's rapid and stable expansion. – End – About Ping An Group Ping An Insurance (Group) Company of China, Ltd. (HKEx:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services, Under the technology-driven "integrated finance + health and senior care" strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its 234 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of 2023, Ping An had RMB11,583,417 million in total assets. The Group ranked 29th in the Forbes Global 2000 list in 2024 and 33rd in the Fortune Global 500 list in 2023. For more information, please visit and follow us on LinkedIn - PING AN. About Ping An Health Ping An Healthcare and Technology Company Limited (stock short name: PA GOODDOCTOR, 01833.HK) is a flagship of Ping An Group's health and senior care ecosystem. As a one-stop health and senior care solution provider, the company provides professional, comprehensive, high-quality services to users. The Company is listed on the Main Board of HKEX (Hong Kong Exchanges and Clearing Limited) and is included in Hang Seng TECH Index. Ping An Health has received "A" from MSCI ESG rating for three consecutive years. In 2023, Ping An Health served more than 26 million paying users from insurance and financial institutions, and 5 million paying users from more than 1,500 business corporate clients. SOURCE Ping An Insurance (Group) Company of China, Ltd.

“Currently More Than 180 Oncolytic Virus Immunotherapies Are In Clinical Trials” Conventionally, the management of cancer was predominantly restricted to surgery, radiation therapy, in addition to chemotherapy. Even though these therapies have shown significant abolition of primary tumors, their allied systemic toxicities and the high incidences of relapse are the foremost limitations. The escalation in prevalence of cancer and the curbs of conventional therapies have propelled the demand of novel targeted therapies which can overcome the limitations and have enhanced specificity and target ability towards the disease. One such approach is using the virus as a therapeutic approach to deliver cancer fighting genes to the tumor cell and thereby inducing an immuno modularity response that will aid to cause death in cancerous cell. This led the development of oncolytic virus therapy as a promising treatment to cure rising cancer malignancies. The oncolytic virus therapy clenches long history which can be backpedalled the late 1950s to 1970s epoch in which the multiple clinical trials and studies were ongoing with the wild type viruses in order to understand a novel approach to treat tumor cells. Moreover, oncolytic viral therapy provides enormous advantage such as higher response towards cancer cells owing to the presence of impaired antiviral defense in addition to better delivery of therapeutic payloads to tumor cells as compared to the conventional treatment which aims to reduce or delays the symptoms of cancer. Download Oncolytic Virus Immunotherapies Clinical Trials Landscape Research: The research and development picked up its pace ever since the oncolytic virus therapy called Oncorine was approved by the National Medical Products Administration (NMPA) to treat Head and neck cancer in the year 2005. However, the drug was only accessible in China owing to the strict rules and regulations. Nevertheless, the approval of Oncorine has provided surplus thrust to the research and development across the globe which led to the approval by FDA for the first viral therapy, T- VEC (Imlygic) to treat melanoma. One of the primary impetuses for the growth of oncolytic virus therapy domain was due to the rising ascendancy of these therapies in the clinical studies. Preliminary data from the clinical trial studies demonstrates that more than 150 clinical researches are currently ongoing for the treatment of innumerable seldom and common diseases such as Alzheimer disease, herpes simplex 1, advanced biliary tract cancer, chronic hepatitis b, refractory malignant ascites as well as hepatocellular carcinoma. The clinical pipeline for the domain of viral therapy is mounting at an incredible gait. For instance, a modified human recombinant type 5 adenovirus with genetic modifications H101 is a novel treatment regimen used to provide treatment for patients suffering from advanced biliary tract cancer. The study is lately in the phase I clinical stage which is sponsored and collaborated by Fudan University. To further enhanced in addition to improve the efficacy, novel viral oncolytic therapy are used in combination with other drugs with the purpose to provide improved and advanced treatment regimen to the patients suffering from cancer. For instance, a novel Telomerase-specific Type 5 Adenovirus OBP-301 viral therapy in conjugation with Carboplatin, Paclitaxel as well as radiation therapy is used to cure adenocarcinoma. The clinical studies in lately in the phase I clinical stage which is sponsored and collaborated by NRG Oncology and National Cancer Institute (NCI). Researches believed that the oncolytic virus therapy clench potential as well as long lasting promising therapeutic effects. As a consequence, multiple pharmaceutical companies along with centers such as City of Hope Comprehensive Cancer Center, New York Medical College, Children's Hospital of Pennsylvania, Mayo Clinic in Arizona, Peking University First Hospital as well as Beijing Tiantan Hospital, Capital Medical University are working recklessly for the purpose to develop advanced oncolytic virus therapy that controls the prognosis of cancer diseases along with other indications such as advanced bladder carcinoma, pancreatic cancer, solid tumor and gastrointestinal cancer. All these examples mentioned above demonstrate that the clinical and translational market for oncolytic virus therapy is growing at an absurd pace.

YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant progress of Telitacicept (RC18), that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren's syndrome (pSS) have completed patient enrollments. Dr. Jianmin Fang, CEO of RemeGen, commented, "This marks further continued progress in RemeGen's research achievements for the treatment of these two diseases and we remain steadfastly committed to providing patients with more efficient and convenient treatment options. The smooth progress of these two clinical trials is an important milestone on the road to achieving this goal." IgA nephropathy is a kidney disease, for which there is currently no cure, caused by the build-up of a germ-fighting protein called immunoglobulin A (IgA) in the kidneys, causing inflammation that can make it harder for the kidneys to filter waste from the blood. A total of 318 patients were enrolled between June 2023 and May 2024 in the clinical study led by Professor Zhang Hong from Peking University First Hospital. It has been designed to evaluate the efficacy and safety of RemeGen's telitacicept in the treatment of patients with primary IgA nephropathy who are at risk of progression to end-stage kidney disease (ESKD). The study uses pre-filled injections which can provide patients with a more convenient administration method and simplified medication use compared with the approved lyophilized powder injection form of telitacicept for the treatment of systemic lupus erythematosus (SLE). Primary Sjögren's syndrome (pSS) is a common rheumatic disease characterized by autoimmune exocrinopathy that clinically manifests as dry eyes and mouth caused by glandular dysfunction as a result of autoimmune damage with multiple organ systems also at risk of being affected. Studies have shown that B-cells are key immune cells involved in the pathogenesis of pSS, and excessive activation of B-cells is a pathogenic indicator of pSS that has long been regarded as a key target for intervention. A total of 381 patients were enrolled between the end of 2022 and May 2024 in the clinical study led by Professor Zeng Xiaofeng from Peking Union Medical College Hospital. This study aims to evaluate the efficacy and safety of telitacicept in the treatment of patients with primary Sjögren's syndrome (pSS) with a primary endpoint of a change in the EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) score from baseline at week 24 of treatment. Telitacicept has previously displayed a significant clinical benefit in a randomized, double-blind, placebo-controlled Phase II clinical trial in the treatment of adult patients with pSS that can significantly improve ESSDAI scores and Multidimensional Fatigue Inventory (MFI-20), thereby reducing immunoglobulin levels in patients. About Telitacicept (RC18) Telitacicept (RC18) is RemeGen's proprietary novel fusion protein for the treatment of autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G(IgG). Telitacicept targets two cell-signaling molecules critical for B-lymphocyte development: B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases. It was granted completed marketing approval by China's National Medical Products Administration (NMPA) to treat systemic lupus erythematosus (SLE) in November 2023. About RemeGen Co. Ltd. Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. For more details, please visit: View original content: SOURCE RemeGen Co., Ltd Company Codes: HongKong:9995, OTC-PINK:REGMY, Shanghai:688331